GLP-1 Medication Cost Savings Strategies 2024: How to Make These Drugs More Affordable

The numbers are staggering — and sobering. A 2025 economic analysis published in JAMA Health Forum estimated that expanding Medicare coverage for GLP-1 receptor agonists would cost the federal government a net $47.7 billion over ten years, even after accounting for $18.2 billion in healthcare savings from reduced obesity-related complications. For the roughly 30 million Medicare-eligible Americans who qualify for these medications, that fiscal reality translates directly into a personal one: GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) remain brutally expensive for most men without robust insurance coverage. If you’re paying out of pocket — or fighting your insurer every 90 days — this is the article you need.

Understanding the cost landscape is the first step. Wegovy’s list price hovers around $1,350 per month, and Zepbound isn’t far behind. These aren’t medications most men can casually add to their budget without a strategy. But here’s what the pharmaceutical system doesn’t advertise loudly enough: there are legitimate, clinically sound ways to reduce what you pay — sometimes dramatically — and none of them require cutting corners on your health.

Manufacturer Savings Programs Are Your First Call

Before you do anything else, go directly to the manufacturer. Novo Nordisk offers the Wegovy Savings Card for commercially insured patients, which can bring monthly costs down to as little as $0 for eligible individuals during an introductory period, with ongoing savings capped at specific thresholds. Eli Lilly runs a comparable program for Zepbound called the Savings Card, potentially reducing your out-of-pocket cost to around $550 per month — and for those who qualify for their income-based program, as low as $25 per month. These programs are not widely advertised, but they are real, and enrollment takes minutes online.

The catch, as with most good things in American healthcare, is eligibility. These savings cards are typically restricted to commercially insured patients — meaning if you’re on Medicare or Medicaid, you’re generally excluded. This is precisely the policy gap that the JAMA Health Forum study was addressing. Medicare Part D currently does not cover GLP-1 medications specifically for obesity (only for diabetes indications), and the research makes clear that even proposed expansions would come with enormous fiscal tradeoffs. Until federal policy catches up, Medicare patients need to explore different channels, including patient assistance programs through the manufacturers themselves, which are means-tested but can provide medications at no cost for qualifying low-income individuals.

Compounding pharmacies entered the conversation aggressively in 2023 and 2024, offering semaglutide and tirzepatide at a fraction of branded drug prices — often $150 to $400 per month. The FDA permits compounding of these drugs under specific shortage designations, but that regulatory window is actively shifting. As of 2024, the FDA has been moving to end shortage status for these medications, which would restrict compounding access significantly. If you’re currently using a compounded version, work with your prescribing physician to understand your timeline and transition plan. The cost savings are real, but so is the regulatory uncertainty.

Working the Insurance System Strategically

Insurance coverage for GLP-1 medications is inconsistent, often employer-plan dependent, and highly negotiable — if you know what levers to pull. Start with a detailed letter of medical necessity from your physician. Insurers are far more likely to approve coverage when your doctor documents not just your BMI, but your specific comorbidities — metabolic syndrome, hypertension, prediabetes, sleep apnea, or cardiovascular risk factors. The JAMA analysis found that healthcare cost offsets from GLP-1 use were meaningful ($18.2 billion projected over a decade across Medicare), and your insurer’s medical director understands this calculus too. Make that argument in writing.

If your initial claim is denied, appeal it. Most men give up after the first denial, which is exactly what insurers count on. A formal appeal — especially one supported by physician documentation and published clinical evidence — succeeds at a meaningful rate. Organizations like the Obesity Action Coalition provide free appeal letter templates specifically for GLP-1 coverage disputes. Use them. If your employer controls your health plan directly (self-insured employers), escalate to HR with a business case: reduced absenteeism, lower long-term healthcare costs, and improved productivity are arguments that CFOs and benefits administrators respond to.

Telehealth platforms have also changed the prescribing landscape substantially. Services like Hims, Ro, and Found offer GLP-1 prescriptions and sometimes bundle compounded versions at lower price points, with the added convenience of virtual visits. The tradeoff is less personalized monitoring compared to an endocrinologist or obesity medicine specialist, so this route works best for men who are otherwise healthy and have done their homework. If you go this route, keep your primary care physician informed — these medications interact with blood pressure, heart rate, and blood sugar in ways that require coordinated oversight.

One underutilized strategy worth mentioning: GoodRx and similar prescription discount services occasionally offer meaningful reductions on brand-name GLP-1 medications, particularly at specific pharmacy chains. The discounts rarely match what manufacturer savings cards offer for commercially insured patients, but for those ineligible for those programs, a GoodRx price can beat the sticker price at the counter. Always compare before you pay.

The Bigger Picture — And What It Means for Your Wallet Long-Term

The JAMA Health Forum analysis makes one thing bracingly clear: even at a policy level, GLP-1 medications present a cost challenge that isn’t going away soon. The researchers found that even under a moderate scenario with a 5% uptake rate, 20% long-term adherence, and a 30% additional price discount beyond current net prices, net Medicare spending would still reach $8 billion over a decade. The implication for individual users is this — price reductions at the federal level will likely be gradual, and strategies to reduce weight regain off medication will become increasingly important both clinically and financially.

This is where the broader picture of metabolic health intersects with cost strategy. Men who use GLP-1 medications most effectively are those who treat the drug as a tool to establish healthier habits — resistance training to preserve lean mass, protein-forward nutrition to support satiety and muscle retention, and sleep optimization to support hormonal balance — not as a permanent crutch. Building those foundations doesn’t just improve your health outcomes; it improves your financial sustainability on these medications, because you may ultimately need lower doses, less frequent dosing, or shorter treatment duration to maintain results.

What This Means For You

GLP-1 medications can be genuinely life-changing for the right candidate — the clinical evidence is robust, and the metabolic benefits are real. But the cost burden is equally real, and navigating it requires the same intentionality you’d bring to your training or nutrition plan. Start with manufacturer savings programs, build your insurance appeal case with physician support and documented comorbidities, understand the compounding landscape and its regulatory timeline, and keep your prescribing physician closely involved regardless of which channel you use. The system isn’t designed to make this easy — but men who approach it strategically can dramatically reduce what they pay while maintaining access to care that works.